Skip to contentR
Roivant Sciences Ltd.
R
ROIVRoivant Sciences Ltd. Q3 2025 · 10-Q
Revenue$2.00M$2.00M−77.8% vs Q3 2024 Net Income-$265.89M-$265.89MN/M vs Q3 2024 EPS Diluted-$0.38-$0.38N/M vs Q3 2024 Operating Income-$339,153,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Roivant Sciences Ltd. · CIK 1635088 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$191,549,000N/M Margins · derivedOperating margin-16966.1%−13923.5 pt vs Q3 2024
Net margin-13301.2%
ended Dec 31, 2025 · filed Feb 6, 2026 · 37 d after period end